戻る Agenda
Session 6 Track E: Good Publication Practice 3: Ethical and Transparent Publication Practice
Session Chair(s)
Diane Moniz Reed, PHARMD
Immuno-Oncology Early Assets, Biomarker Publications and Scientific Content
Bristol-Myers Squibb, United States
Learning Objective : - Discuss why GPP Guidelines are relevant to Medical Writers and all stakeholders involved with industry sponsored presentations and publications
- Describe the key guidelines that are considered industry best practice
- Explain the main elements of the newly-published GPP3 that are particularly important to Medical Writers
- Describe how to access the key Good Publication Practice Guidelines, including GPP3
Speaker(s)
Good Publication Practice 3: Ethical and Transparent Publication Practice Overview and Panel Discussion
Diane Moniz Reed, PHARMD
Bristol-Myers Squibb, United States
Immuno-Oncology Early Assets, Biomarker Publications and Scientific Content
Overview and Panel Discussion
Kim Pepitone
Cactus Communications, Inc., United States
Scientific Director
Overview and Panel Discussion
Eileen Girten, MS
Pfizer, United States
Medical Writing Therapeutic Area Lead
Overview and Panel Discussion
Christian Klem
AstraZeneca Pharmaceuticals, United States
Sr. Director, Global Scientific Publications & Communications, CV